Objective: Rupture and hemorrhage of corpus luteum cyst is one of the common acute abdominal diseases in gynecology, which occurs in the middle and late menstrual cycle, and is often seen in women of childbearing age, often under the inducement of exercise and sexual life. There are few reports about drug-induced rupture and hemorrhage of corpus luteum cyst. Chronic myeloid leukemia (CML) is a common hematological disease and a chronic clonal myeloproliferative disease. Imatinib is a first-line drug for the treatment of chronic myeloid leukemia, and its efficacy and safety have been widely recognized, but there are still some adverse reactions. Among them, it is rare that the drug causes ovarian corpus luteum rupture and bleeding. In our clinical work, we just treated a patient with recurrent ovarian luteal cyst rupture and bleeding from imatinib, and followed up the whole course of the patient's pathogenesis, diagnosis and treatment effect. Therefore, this paper analyzes the clinical data and treatment of the case, in order to improve the clinical understanding and treatment of recurrent ovarian luteal cyst rupture and hemorrhage induced by imatinib. Methods: The clinical data and treatment of 1 case of recurrent ovarian corpus luteum cyst rupture bleeding from imatinib were analyzed, and the therapeutic effect was followed up. Results: Imatinib led to 6 times of corpus luteum rupture bleeding, which were successfully treated with conservative treatment. After taking Diane-35, the patient did not have corpus luteum rupture bleeding once again. And no adverse drug reactions. Conclusion: Imatinib can cause recurrent ovarian luteal cyst rupture and bleeding, conservative treatment is often effective. Diane-35 can effectively prevent and treat recurrent ovarian luteal cyst rupture and bleeding induced by imatinib. And the incidence of adverse drug reactions was low. But the specific mechanism that imatinib causes rupture of recurrent ovarian luteal cyst is unclear.
| Published in | Journal of Gynecology and Obstetrics (Volume 9, Issue 4) |
| DOI | 10.11648/j.jgo.20210904.11 |
| Page(s) | 100-103 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Imatinib, Corpus Luteum Cyst, Treatment
| [1] | Xing Xie, Beihua Kong, Tao Duan, et al. Obstetrics and Gynecology ninth edition [M]. Beijing: People's Health Publishing House, 2018: 77-78. |
| [2] | Hui Liu, Hong Xiang, Ruixue Mu, et al. Value of transvaginal two-dimensional contrast-enhanced ultrasonography in diagnosing atypical ovarian corpus luteum hematoma [J] BioMed Research International, 2018, 2018 (5): 1-11. |
| [3] | Huiqing Wang, Jie Zhan. Ultrasonographic features and clinical analysis of rupture of corpus luteum cyst [J]. Journal of Medical Imaging, 2020, 30 (6): 116-118. |
| [4] | HUANG X, CORTES J, KANTARJIAN H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy [J]. Cancer, 2012, 118 (12): 3123-3127. |
| [5] | Yanzhi Zhang, Ling Qin. A case of chronic myeloid leukemia with myelofibrosis in children [J]. Hainan Medical Journal, 2021, 32 (8): 1074-1075. |
| [6] | Gugliotta G, Castagnetti F, Apolinari MA, et al. First-Line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies [J]. Drugs, 2014, 74 (6): 627-643. |
| [7] | Fei Li, Xiaojie Zhang, Rongyan Zhang, et al. Imatinib for the first-line treatment of chronic myeloid leukemia in chronic phase: a single center retrospective analysis of 10 years [J]. Chinese Journal of Clinical Oncology, 2016, 43 (10): 432-437. |
| [8] | Kagimoto Y, Mizuashi M, Kikuchi K, et al. Lichenoid drug eruption with hyperpigmentation caused by imatinib mesylate [J]. International Journal of Dermatology, 2014, 53 (3): e161- e162. |
| [9] | Hongmei Zhu. Literature analysis of 224 cases of imatinib mesylate adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2018, 15 (12): 733-737. |
| [10] | Jun Ma, Jianmin Luo, Yan Wen, et al. Clinical study of domestic imatinib mesylate in the treatment of newly diagnosed chronic myeloid leukemia in chronic phase [J]. Journal of Clinical Hematology, 2018, 31 (11): 841-845. |
| [11] | Xiaolan He, Hong Gao, Shiyi Liu. Study on the differential diagnosis of ovarian corpus luteum rupture and ectopic pregnancy rupture by transvaginal color Doppler ultrasound [J]. Journal of North Sichuan Medical College, 2019, 34 (5): 600-603. |
| [12] | Hua-Di Yang, Meng-Ting Xia, Yi-Feng Shao, et al. Recurrent ovarian hemorrhage in a patient with aplastic anemia: a case report [J]. Medicine, 2018, 97 (27): 11409-11414. |
| [13] | Fengjiao Fan, Jixiang He, zhangkun Li, Yirong Jiang. A case of drug-induced lung injury induced by imatinib [J]. Journal of Clinical Internal Medicine, 2021, 38 (4): 282-283. |
| [14] | Xiayun Liu, Yanna Lin. Clinical analysis of 60 cases of rupture and hemorrhage of ovarian corpus luteum cyst [J]. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine, 2017, 27 (23): 109-110. |
| [15] | Xing Xie, Beihua Kong, Tao Duan, et al. Obstetrics and Gynecology ninth edition [M]. Beijing: People's Health Publishing House, 2018: 369-370. |
| [16] | Ling Qin. Diane 35 combined with metformin in the treatment of polycystic ovary syndrome [J]. Journal of practical gynecological endocrinology, 2019, 24 (6): 78-78. |
APA Style
Huan Xia, Weiwei Huang, Yang Song, Wenying Liu, Huajuan Dong, et al. (2021). Analysis of the Diagnosis and Treatment of Recurrent Rupture and Hemorrhage of Ovarian Corpus Luteum Cyst Induced by Imatinib. Journal of Gynecology and Obstetrics, 9(4), 100-103. https://doi.org/10.11648/j.jgo.20210904.11
ACS Style
Huan Xia; Weiwei Huang; Yang Song; Wenying Liu; Huajuan Dong, et al. Analysis of the Diagnosis and Treatment of Recurrent Rupture and Hemorrhage of Ovarian Corpus Luteum Cyst Induced by Imatinib. J. Gynecol. Obstet. 2021, 9(4), 100-103. doi: 10.11648/j.jgo.20210904.11
AMA Style
Huan Xia, Weiwei Huang, Yang Song, Wenying Liu, Huajuan Dong, et al. Analysis of the Diagnosis and Treatment of Recurrent Rupture and Hemorrhage of Ovarian Corpus Luteum Cyst Induced by Imatinib. J Gynecol Obstet. 2021;9(4):100-103. doi: 10.11648/j.jgo.20210904.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.jgo.20210904.11,
author = {Huan Xia and Weiwei Huang and Yang Song and Wenying Liu and Huajuan Dong and Li Qiu and Jiming Chen},
title = {Analysis of the Diagnosis and Treatment of Recurrent Rupture and Hemorrhage of Ovarian Corpus Luteum Cyst Induced by Imatinib},
journal = {Journal of Gynecology and Obstetrics},
volume = {9},
number = {4},
pages = {100-103},
doi = {10.11648/j.jgo.20210904.11},
url = {https://doi.org/10.11648/j.jgo.20210904.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jgo.20210904.11},
abstract = {Objective: Rupture and hemorrhage of corpus luteum cyst is one of the common acute abdominal diseases in gynecology, which occurs in the middle and late menstrual cycle, and is often seen in women of childbearing age, often under the inducement of exercise and sexual life. There are few reports about drug-induced rupture and hemorrhage of corpus luteum cyst. Chronic myeloid leukemia (CML) is a common hematological disease and a chronic clonal myeloproliferative disease. Imatinib is a first-line drug for the treatment of chronic myeloid leukemia, and its efficacy and safety have been widely recognized, but there are still some adverse reactions. Among them, it is rare that the drug causes ovarian corpus luteum rupture and bleeding. In our clinical work, we just treated a patient with recurrent ovarian luteal cyst rupture and bleeding from imatinib, and followed up the whole course of the patient's pathogenesis, diagnosis and treatment effect. Therefore, this paper analyzes the clinical data and treatment of the case, in order to improve the clinical understanding and treatment of recurrent ovarian luteal cyst rupture and hemorrhage induced by imatinib. Methods: The clinical data and treatment of 1 case of recurrent ovarian corpus luteum cyst rupture bleeding from imatinib were analyzed, and the therapeutic effect was followed up. Results: Imatinib led to 6 times of corpus luteum rupture bleeding, which were successfully treated with conservative treatment. After taking Diane-35, the patient did not have corpus luteum rupture bleeding once again. And no adverse drug reactions. Conclusion: Imatinib can cause recurrent ovarian luteal cyst rupture and bleeding, conservative treatment is often effective. Diane-35 can effectively prevent and treat recurrent ovarian luteal cyst rupture and bleeding induced by imatinib. And the incidence of adverse drug reactions was low. But the specific mechanism that imatinib causes rupture of recurrent ovarian luteal cyst is unclear.},
year = {2021}
}
TY - JOUR T1 - Analysis of the Diagnosis and Treatment of Recurrent Rupture and Hemorrhage of Ovarian Corpus Luteum Cyst Induced by Imatinib AU - Huan Xia AU - Weiwei Huang AU - Yang Song AU - Wenying Liu AU - Huajuan Dong AU - Li Qiu AU - Jiming Chen Y1 - 2021/07/10 PY - 2021 N1 - https://doi.org/10.11648/j.jgo.20210904.11 DO - 10.11648/j.jgo.20210904.11 T2 - Journal of Gynecology and Obstetrics JF - Journal of Gynecology and Obstetrics JO - Journal of Gynecology and Obstetrics SP - 100 EP - 103 PB - Science Publishing Group SN - 2376-7820 UR - https://doi.org/10.11648/j.jgo.20210904.11 AB - Objective: Rupture and hemorrhage of corpus luteum cyst is one of the common acute abdominal diseases in gynecology, which occurs in the middle and late menstrual cycle, and is often seen in women of childbearing age, often under the inducement of exercise and sexual life. There are few reports about drug-induced rupture and hemorrhage of corpus luteum cyst. Chronic myeloid leukemia (CML) is a common hematological disease and a chronic clonal myeloproliferative disease. Imatinib is a first-line drug for the treatment of chronic myeloid leukemia, and its efficacy and safety have been widely recognized, but there are still some adverse reactions. Among them, it is rare that the drug causes ovarian corpus luteum rupture and bleeding. In our clinical work, we just treated a patient with recurrent ovarian luteal cyst rupture and bleeding from imatinib, and followed up the whole course of the patient's pathogenesis, diagnosis and treatment effect. Therefore, this paper analyzes the clinical data and treatment of the case, in order to improve the clinical understanding and treatment of recurrent ovarian luteal cyst rupture and hemorrhage induced by imatinib. Methods: The clinical data and treatment of 1 case of recurrent ovarian corpus luteum cyst rupture bleeding from imatinib were analyzed, and the therapeutic effect was followed up. Results: Imatinib led to 6 times of corpus luteum rupture bleeding, which were successfully treated with conservative treatment. After taking Diane-35, the patient did not have corpus luteum rupture bleeding once again. And no adverse drug reactions. Conclusion: Imatinib can cause recurrent ovarian luteal cyst rupture and bleeding, conservative treatment is often effective. Diane-35 can effectively prevent and treat recurrent ovarian luteal cyst rupture and bleeding induced by imatinib. And the incidence of adverse drug reactions was low. But the specific mechanism that imatinib causes rupture of recurrent ovarian luteal cyst is unclear. VL - 9 IS - 4 ER -
Information
Email: